Natixis Macrogenics Inc Transaction History
Natixis
- $17.6 Billion
- Q3 2024
Shares
2 transactions
Others Institutions Holding MGNX
# of Institutions
132Shares Held
55.4MCall Options Held
215KPut Options Held
238K-
Bellevue Group Ag Kuesnacht, V89.93MShares$32.4 Million0.55% of portfolio
-
Armistice Capital, LLC New York, NY6.26MShares$20.4 Million0.34% of portfolio
-
Black Rock Inc. New York, NY5.4MShares$17.6 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.36MShares$14.2 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.54MShares$11.5 Million0.01% of portfolio
About MACROGENICS INC
- Ticker MGNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 61,458,800
- Market Cap $200M
- Description
- MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...